Introduction {#s1}
============

C-reactive protein (CRP) is a nonspecific marker of systemic inflammation that predicts incident type 2 diabetes. Chronic low-grade inflammation may induce insulin resistance and is a candidate pathway leading from obesity to diabetes \[[@pmed-0050155-b001]--[@pmed-0050155-b003]\]. Several population-based observational studies suggest an independent role for CRP in the development of insulin resistance and diabetes, but it is unclear whether this association is a causal one or the consequence of imperfect adjustment for adiposity and other confounding factors \[[@pmed-0050155-b004]--[@pmed-0050155-b010]\]. Preventing or delaying onset of diabetes and its complications is an important therapeutic aim, and there is interest in inflammatory effectors including CRP as drug targets \[[@pmed-0050155-b011],[@pmed-0050155-b012]\]. It is therefore highly desirable to establish which mediators in the inflammatory cascade are causal for diabetes.

Mendelian randomization involves comparison of phenotype and genotype effects in observational studies \[[@pmed-0050155-b013]\]. If the association between a modifiable risk factor and disease is causal, the genetic variant associated with this risk factor should be related to the disease outcome to the extent predicted by the magnitude of its association with the risk factor. The approach is based on two concepts. First, random allocation of parental alleles leads to lifetime exposure to differing levels of the risk factor, in the present case CRP haplotype and heritable CRP level \[[@pmed-0050155-b014],[@pmed-0050155-b015]\]. Second, the genetically influenced component of variation in the risk factor will generally be unaffected by confounding and reverse causation, in contrast to the variation associated with environmental influences \[[@pmed-0050155-b013],[@pmed-0050155-b016],[@pmed-0050155-b017]\].

We are aware of one previous study of CRP and diabetes employing the Mendelian randomization technique in a European population \[[@pmed-0050155-b004]\]. It found that a rare haplotype was associated with a modest increase in risk of diabetes but did not employ instrumental variables analysis to show that the effect of circulating CRP on diabetes risk was unconfounded. Confounding was demonstrated in a study of CRP and metabolic syndrome variables \[[@pmed-0050155-b018]\]. The present study examines the causal nature of the relation between serum CRP and development of diabetes risk using Mendelian randomization. We measured homeostasis model assessment-insulin resistance (HOMA-IR) \[[@pmed-0050155-b019]\] and hemoglobin A1c (HbA1c) as an index of glycemic control, as well as determining diabetes caseness, in the Whitehall II Study. The continuous traits provide adequate statistical power for an instrumental analysis of the unconfounded and unbiased (by reverse causation and regression dilution bias) effects of CRP on HbA1c and HOMA-IR. Three tagging SNPs in the *CRP* gene allowed construction of haplotypes that were used as instrumental variables. We carried out a pooled analysis in relation to diabetes caseness as the same haplotypes were available in the prospective Northwick Park Heart Study II (NPHSII). Data from the Wellcome Trust Case Control Consortium (WTCCC) further allowed us to analyze three SNPs in tight long-range linkage disequilibrium (LD) with our tagging SNPs among 1,923 diabetes cases and 2,932 controls.

Methods {#s2}
=======

Index Study: Whitehall II Study {#s2a}
-------------------------------

In 1985--1988, all nonindustrial civil servants aged between 35 and 55 y, in 20 departments in central London were invited to a medical examination at their workplace \[[@pmed-0050155-b020],[@pmed-0050155-b021]\]. With 73% participation, the cohort included 10,308 participants at study entry. Of these individuals, 6,156 participated in screening in 2003--2004 (study phase 7) and were genotyped for variants in the *CRP* gene. Excluding non-Europeans, those with missing phase 7 CRP, neither HOMA-IR nor HbA1c concentration, missing *CRP* SNPs, or with unreliable haplotypes, the final sample included 5,274 (3,849 men, 1,425 women) participants aged 50 to 74 y (mean 61 y), all of whom signed an informed consent. CRP measurements at mean age 49 y were available for 4,674 (3,433 men, 1,241 women).

### Measurements. {#s2a1}

Age, sex, body mass index (BMI), waist circumference, blood pressure, smoking, physical activity, socioeconomic position, coronary heart disease, and diabetes status were measured at mean ages 49 and 61 y. Weight was measured in underwear to the nearest 0.1 kg on Soehnle electronic scales. Height was measured in bare feet to the nearest 1 mm using a stadiometer with the participant standing erect with head in the Frankfurt plane. Waist circumference, taken as the smallest circumference at or below the costal margin, was measured with participants unclothed in the standing position utilizing a fiberglass tape measure at 600 g tension. Venous blood was taken in the fasting state or at least 5 h after a light, fat-free breakfast, before undergoing a 2-h 75-g oral glucose tolerance test \[[@pmed-0050155-b022]\]. Serum triglycerides were measured by automated enyzmic colorimetric methods. HDL cholesterol was measured using phosphotungstate precipitation. Glucose was measured in fluoride plasma by an electrochemical glucose oxidase method. Insulin was measured by radioimmunoassay using polyclonal guinea pig antiserum at age 49 y and by double antibody ELISA at age 61 y.

### C-reactive protein genotyping. {#s2a2}

DNA was extracted from blood samples using magnetic bead technology (Geneservice). Using validated genotype data (minor allele frequency \>5%) from participants of European descent from the National Heart Lung and Blood Institute (NHLBI) Programs for Genomic Applications (PGA) database (<http://pga.mbt.washington.edu/>), and HapMap (<http://www.hapmap.org/>), we examined the pattern of LD across the CRP gene. We used the haplotype LD *r*^2^ method to select a set of tagging (t) SNPs capable of capturing maximum haplotype diversity using TagIT (<http://popgen.biol.ucl.ac.uk/software.html>). We genotyped three SNPs in the *CRP* gene (+1444T \> C \[rs1130864\]; +2302G \> A \[rs1205\]; and +4899T \> G \[rs 3093077\]) using the ABI Prism 7900HT Sequence Detection System for both PCR and allelic discrimination (Applied Biosystems) under standard conditions. CRP +2303 and +4899 were found to be in Hardy Weinberg Equilibrium (HWE) (chisq *p* \> 0.05), however +1444 was not in HWE (*p* = 0.003). Blind re-genotyping of the +1444 SNP (*n* = 678) in a different laboratory produced a mismatch rate of 0.5% suggesting that genotyping errors were not responsible. A repeated blood sample from 553 participants showed the genotyping error rate was \<1% for each SNP.

### C-reactive protein. {#s2a3}

CRP was measured in serum stored at −80 °C using a high-sensitivity immunonephelometric assay in a BN ProSpec nephelometer (Dade Behring). Values below the detection limit (0.154 mg/l) were assigned a value of 0.077 mg/l (333 \[7.1%\] at age 49 y, 104 \[2.0%\] at age 61 y). Samples from both study phases were analyzed at the same time. Intra- and interassay coefficients of variation were 4.7% and 8.3%. To measure short-term biological variation and laboratory error, a repeated sample was taken from a subset of 150 participants at mean age 49 y and 533 participants at mean age 61 y (average time between samples 32 and 24 d, respectively). Reliability between samples was assessed with intraclass correlation: *r* = 0.83 at mean age 49 y, and *r* = 0.57 at mean age 61 y.

### Diabetes. {#s2a4}

Diabetes status was determined at mean ages 49, 56, and 61 y on the basis of self-report of doctor diagnosis, use of diabetes medication or 75 g OGTT. Diabetes was defined by 2-h glucose ≥ 11.1 mmol/l or fasting glucose ≥ 7 mmol/l \[[@pmed-0050155-b023]\].

### HbA1c and HOMA-IR. {#s2a5}

HbA1c was measured in EDTA whole blood on a calibrated HPLC system with automated hemolysis prior to injection. HbA1 is resolved as a separate peak, which does not interfere with HbA1c quantitation. HOMA-IR was calculated as (fasting glucose \[mmol/l\] × fasting insulin \[mU/l\]/22.5) \[[@pmed-0050155-b019]\]. Nonfasting participants were assigned a missing value (*n* = 435, 9.1%).

Data Analysis {#s2b}
-------------

### Standard regression analysis. {#s2b1}

We used age- and sex-adjusted least square regression analysis to assess (1) the association of haplotypes (see below) with circulating CRP levels at baseline and follow-up, and with potential confounding factors; (2) the associations of potential confounding factors with circulating CRP levels and with HbA1c and HOMA-IR at follow-up; and (3) the association between circulating CRP levels with HbA1c and HOMA-IR in a multivariable model. The haplotype-confounder associations were computed to test our underlying hypothesis that genetic variants in *CRP* would not be associated with confounding factors that effect conventional epidemiological associations. We used Cox regression to assess associations between CRP levels at baseline and incident diabetes, and logistic regression analysis to assess associations between haplotype and prevalent diabetes with a binary indicator for study (Whitehall II or NPHSII) in the pooled analysis.

### Haplotype construction. {#s2b2}

We constructed haplotypes with the genetic data analysis program SIMHAP (see [http://www.genepi.com/au/project/simhap](http://www.genepi.org.au/simhap.html ), obtained May 2, 2007), using 1,000 iterations and a posterior probability ≥ 0.95. Four haplotypes of SNPs +1444, +2302, and +4899 (CAT, CGG, CGT, and TGT) remained in the analysis in which genetic variants were used to determine the association of CRP with diabetes, HbA1c, and HOMA-IR.

### Instrumental variables analysis. {#s2b3}

An instrumental variables analysis, in which *CRP* haplotypes were used as instrumental variables for the unconfounded and unbiased effect of CRP on HbA1c, was undertaken using two-stage least squares method. In these analyses we use a model for the haplotype-CRP association that assumes each of a participant\'s two haplotypes contributes additively to his/her value of CRP, as in a previous study \[[@pmed-0050155-b018]\]. We compared results from the instrumental variable estimates of the association of CRP with HbA1c to those from ordinary linear regression using the Durbin form of the Durbin-Wu-Hausman statistic. We used the *F*-statistics from the first-stage regressions to evaluate the strength of the instruments (*F* \> 10 indicates sufficient strength to ensure the validity of instrumental variable methods) \[[@pmed-0050155-b024]\].

### General analytic procedures. {#s2b4}

There was no statistical evidence that the associations we examined differed by sex, although previous studies have been inconsistent in this respect \[[@pmed-0050155-b025]--[@pmed-0050155-b027]\]. Because of skewness, we logarithmically transformed CRP in the analyses, using log base 2 so that we could present associations per doubling of CRP \[[@pmed-0050155-b017],[@pmed-0050155-b018],[@pmed-0050155-b028]\], and transformed HbA1c and HOMA-IR to the natural logarithm. We excluded observations with serum CRP \> 10 mg/l, indicating an acute phase reaction, in analyses with serum CRP (*n* = 80 at age 49 y, *n* = 182 at age 61 y). Analyses were performed with Stata 8.2 or 9.2 (Stata Institute).

Replication Studies {#s2c}
-------------------

We replicated our analysis in two independent samples: NPHSII and WTCCC \[[@pmed-0050155-b029],[@pmed-0050155-b030]\]. The three tagging SNPs utilized here were typed in NPHSII (2,173 men, mean age 56 y), and cases of diabetes (*n* = 174) were identified to the end of 2005 by searching medical records for physician diagnosis and treatment \[[@pmed-0050155-b029]\]. Within the WTCCC sample, none of the SNPs that we have used here were available \[[@pmed-0050155-b031]\]. However, three alternative SNPs, identified using Ensembl (<http://www.ensembl.org/index.html>), were included on the Affymetrix 500K array and are in long-range LD with our tagging SNPs, as follows: rs12760041 with rs1130864 (*r*^2^ = 0.84), rs2592889 with rs1205 (*r*^2^ = 0.75), and rs11265260 with rs3093077 (*r*^2^ = 1.00). An analysis based on 1,923 cases of diabetes and 2,932 controls was used to examine genotype-diabetes associations. Each genotype was found to be in Hardy Weinberg Equilibrium with the exception of rs2592889 among cases (*p* = 0.003).

Results {#s3}
=======

Participants were on average 60.9 y of age, the majority was men and from executive officer and senior administrative employment grades ([Table 1](#pmed-0050155-t001){ref-type="table"}). There were 354 (6.7%) cases of diabetes at follow-up. As expected, haplotypes were associated with circulating CRP levels ([Table 2](#pmed-0050155-t002){ref-type="table"}) but not with risk factors at baseline or follow-up (all *p* ≥ 0.07) except in one case at baseline: CGG-occupational status (*p* = 0.038). In contrast, all risk factors were associated with serum CRP, HbA1c, and HOMA-IR except physical activity level (CRP only) ([Table 3](#pmed-0050155-t003){ref-type="table"}).

###### 

Participant Characteristics
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###### 

Association between *CRP* Haplotypes and Serum CRP Concentration
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###### 

Contemporaneous Associations of Risk Factors for Diabetes with Serum CRP Concentration, HbA1c, and HOMA-IR at Mean Age 61 y (Adjusted for Age and Sex)

![](pmed.0050155.t003)

Baseline serum CRP was a strong predictor of incident diabetes after adjustment for age and sex (hazard ratio \[HR\] for doubling of CRP 1.39 (95% confidence interval \[CI\] 1.29--1.51) ([Table 4](#pmed-0050155-t004){ref-type="table"}). Controlling for general and central obesity attenuated the CRP effect considerably, and after extensive adjustment the HR was reduced by 51%. After adjustment for age and sex, higher contemporaneous and previous serum CRP concentrations were associated with increased HOMA-IR and HbA1c ([Table 5](#pmed-0050155-t005){ref-type="table"}). Further adjustment for risk factors greatly attenuated these associations.

###### 

Relation between Serum CRP at Mean Age 49 y and Incident Type 2 Diabetes among Participants of European Origin during 13.1 y Follow-up
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###### 

Prospective and Cross-Sectional Associations of Serum CRP with HbA1c and HOMA-IR

![](pmed.0050155.t005)

Median levels of HbA1c and HOMA-IR did not vary by *CRP* haplotypes, suggesting that these haplotypes have no effect on diabetes risk ([Table 6](#pmed-0050155-t006){ref-type="table"}), although they are consistently associated with serum CRP concentrations.

###### 

Relation between *CRP* Haplotypes, HOMA-IR, and HbA1c at Mean Age 61 y among Participants of European Origin

![](pmed.0050155.t006)

*F*-statistics from the first-stage regressions in the instrumental variable models were greater than 10 (HbA1c, 18.3 for contemporaneous and 17.0 for previous serum CRP; HOMA-IR, 15.3 and 15.8, respectively) indicating sufficient strength to ensure validity of instrumental variable methods in these data. [Table 7](#pmed-0050155-t007){ref-type="table"} compares the magnitudes of association of CRP with HbA1c and HOMA-IR obtained from the age- and sex-adjusted ordinary least squares regression analysis and the unadjusted instrumental variables analysis. While the ordinary least squares regression analysis indicated positive associations of CRP levels with HbA1c and HOMA-IR (*p* \< 0.0001), the instrumental variables analysis consistently suggested no such association (*p* \> 0.60), though this was imprecisely estimated. The Durbin-Wu-Hausman test for difference between the linear regression and instrumental variables estimates approached significance in three of four comparisons and highly significant for contemporaneous serum CRP with HOMA-IR as outcome. Coefficients from the confounder-adjusted linear regressions were similar to those from the instrumental variables analyses, suggesting no causal CRP effect.

###### 

Comparison of Cross-Sectional and Prospective Associations between CRP and HbA1c Concentration Estimated by Linear Regression and with Instrumental Variables (with *CRP* Haplotypes as Instruments)

![](pmed.0050155.t007)

NPHSII {#s3a}
------

Haplotype-serum CRP associations were similar to those observed in Whitehall II ([Table S1](#pmed-0050155-st001){ref-type="supplementary-material"}). None of the four haplotypes was associated with potential confounding variables age, BMI, systolic BP, serum triglycerides, and cholesterol ([Table S2](#pmed-0050155-st002){ref-type="supplementary-material"}). Serum CRP was a risk factor for incident diabetes (age adjusted HR for doubling of CRP 1.27 \[95% CI 1.11--1.44\]). The effect was attenuated after controlling for the risk factors above (HR = 1.08 \[0.93--1.24\]).

Pooled analysis of *CRP* haplotypes and prevalent cases of diabetes (*n* = 522) in Whitehall II and NPHSII produced null findings ([Table 8](#pmed-0050155-t008){ref-type="table"}). Among TGT homozygotes the reduced risk of diabetes is counterfactual given the direct association between TGT haplotype number and serum CRP ([Table 2](#pmed-0050155-t002){ref-type="table"}).

###### 

Pooled Analysis of Association between *CRP* Haplotypes and Type 2 Diabetes in Whitehall II and NPHSII

![](pmed.0050155.t008)

WTCCC Sample {#s3b}
------------

Case-control analysis of diabetes and the three SNPs in long-range LD with the SNPs of interest produced no evidence of association. Odds ratios (95% CI) were 0.98 (0.92--1.04) for rs12760041, 1.04 (0.98--1.12) for rs2592889, and 0.91 (0.81--1.03) for rs11265260.

Discussion {#s4}
==========

This large study provides evidence that systemic CRP levels are not responsible for development of insulin resistance, hyperglycemia, or diabetes. The finding does not preclude the possibility that inflammatory signals contribute to causal processes leading to diabetes. We obtained a clear signal, using Mendelian randomization, that the association between systemic CRP and diabetes risk is not causal. However, the nature of the prospective relation between serum CRP and diabetes risk points to the potential effects of more proximal mediators in the inflammatory cascade.

Our underlying assumption was confirmed that genetic variants in *CRP* would not be associated with socioeconomic, lifestyle, and biological confounding factors, enabling us to estimate the unconfounded effect of CRP on HbA1c and HOMA-IR by means of the variation in systemic CRP due to four *CRP* haplotypes. No such effect was detected.

In addition to the analysis of Whitehall II data, further support for our conclusion concerning CRP and diabetes is provided by NPHSII and WTCCC. NPHSII haplotype and disease caseness data allowed a pooled haplotype-diabetes analysis with Whitehall II, which confirmed our null findings. Among almost 2,000 cases of diabetes and 3,000 controls in the WTCCC sample, we were able to identify three SNPs distant from the *CRP* locus but in tight LD with the SNPs we typed. None of these was associated with diabetes caseness.

Several issues may compromise the value of Mendelian randomization approach in assessing causality \[[@pmed-0050155-b013]\]. First, common genetic variants determining significant proportions of variance in the exposure of interest are needed. For the *CRP* haplotypes in question, this is the case here and in other independent studies \[[@pmed-0050155-b015],[@pmed-0050155-b018],[@pmed-0050155-b032]--[@pmed-0050155-b038]\]. Second, the association of the genotype (instrumental variable) with phenotype has to be strong enough for the instrumental variables analysis to be consistent. The *F*-statistic was clearly above the threshold of 10 used to identify the problem of a weak instrument \[[@pmed-0050155-b024]\], although a larger study would yield greater precision in the estimates from instrumental variables analysis. Third, the Mendelian randomization approach may be open to confounding if the genetic variants used as instruments have multiple effects on phenotype (pleiotropy) or if the variant is in LD with another genetic variant that differently influences the pathway of interest. With respect to the null associations observed in our study we think pleiotropy is unlikely. The variants that we used to generate the *CRP* haplotypes used here as instrumental variables are in very close LD with variation within a transcription factor binding site located 5′ of the *CRP* gene, which is associated with circulating concentrations of CRP and thought to be functional \[[@pmed-0050155-b039],[@pmed-0050155-b040]\]. It is unlikely that the variation in circulating CRP associated with this marker (or those, like our haplotypes, in LD with it) is substantially involved in other phenotypes affecting inflammatory processes because of their role as a transcription factor binding site. Fourth, developmental compensation, or canalization, during fetal development may provide resistance to the influence of a genetic variant through permanent changes in cellular function that counterbalance the genetic effect. Such mechanisms are a potential source of bias in all Mendelian randomization studies. Despite this potential bias, the method has confirmed established associations such as that of LDL cholesterol with cardiovascular disease risk \[[@pmed-0050155-b041]\].

Our findings are consistent with a previous study that examined HOMA-IR as an outcome \[[@pmed-0050155-b018]\]. To our knowledge two previous studies have examined the association of variation in the *CRP* gene in relation to the binary outcome of type 2 diabetes \[[@pmed-0050155-b004],[@pmed-0050155-b042]\]. We find that the rare CGG haplotype is associated with serum CRP level, but we do not replicate the modest link with diabetes observed in the Rotterdam study \[[@pmed-0050155-b004]\]. Among Pima Indians (a population with very high levels of risk for type 2 diabetes) the rs133552 SNP, in the promoter region of *CRP*, was associated with diabetes risk \[[@pmed-0050155-b042]\]. The *CRP* haplotypes used in the present study index the rare allele of rs133552, thus it is unlikely that our null finding is due to unmeasured genetic variation. The consistent lack of association in our primary study, our two replication samples including the large WTCCC, and a large case-control study of Finnish participants \[[@pmed-0050155-b043]\], provides compelling evidence that CRP is not related to diabetes in European populations. Further replication of the genetic association in the Pima Indian population would shed light on this putative ethnic difference.

If glucose intolerance and insulin resistance have inflammatory causes, mediators should be sought among cytokines more proximal than CRP to the start of the inflammatory cascade. Gene expression of CRP occurs mainly in hepatocytes, regulated by interleukin (IL)-6 originating from adipocytes and immune tissue. This cytokine and tumor necrosis factor (TNF)-α are candidate mediators for the proposed inflammatory link between increased body fat and induction of insulin resistance locally in adipocytes and in distant tissues \[[@pmed-0050155-b001],[@pmed-0050155-b044],[@pmed-0050155-b045]\]. Other inflammatory mechanisms, such as complement pathways, may also be important \[[@pmed-0050155-b046]\].

Rodent models of obesity provide evidence that adipose expression of TNF-α is associated, reversibly, with insulin resistance and reduced glucose uptake and fatty acid oxidation \[[@pmed-0050155-b003],[@pmed-0050155-b047]\].

In humans, SNPs in *TNF* have been linked with diabetes, obesity, and obesity phenotypes \[[@pmed-0050155-b043],[@pmed-0050155-b048]\]. However, a short-term trial of the anti-TNF-α drug etanercept in individuals with the metabolic syndrome, did not increase insulin sensitivity despite a decrease in CRP levels \[[@pmed-0050155-b049]\]. With respect to *IL6*, there is evidence for associations of gene variants with diabetes \[[@pmed-0050155-b043],[@pmed-0050155-b050]\], insulin sensitivity \[[@pmed-0050155-b051]\], and metabolic syndrome \[[@pmed-0050155-b052]\]. Whether obesity leads to insulin resistance primarily as a result of chronic low grade inflammation or metabolic alterations remains an important question.
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